nach oben

Endocrine

Erschienen in:

02.01.2024 | Original Article

The effect of SGLT2i on the GH/IGF1 axis in newly diagnosed male T2D patients – a prospective, randomized case–control study

verfasst von: Jing Lin, Liqin Zhan, Zheng Chen, Xiaying Lin, Rongfeng Zhu

Erschienen in: Endocrine | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the effect of SGLT2i on the GH/IGF1 axis in male patients with newly diagnosed type 2 diabetes (T2D).

Methods

Sixty male patients with newly diagnosed T2D were recruited, and randomly assigned to Metformin+SGLT2i group or Metformin group after baseline assessment. All patients received standard lifestyle interventions, and blood indices were obtained before and after 12 weeks of treatment.

Results

After 12 weeks of treatment with Metformin+SGLT2i, there were noteworthy improvements in patients’ FPG (Fasting plasma glucose), HBA1c, HOMA-IR, HOMA-β, TyG (Triglyceride−glucose) index and UACR (P < 0.05). Both IGF1 (P = 0.01) and the IGF1/IGFBP3 ratio (P < 0.01) considerably increased, while GH and IGFBP3 did not show significant changes. When comparing Metformin+SGLT2i group to Metformin group, SGLT2i significantly improved HOMA-IR [P = 0.04], and elevated IGF1/IGFBP3 ratio [P = 0.04], SGLT2i showed a tendency of increasing IGF1 (P = 0.10), but this was not statistically meaningful. There was no effect on GH and IGFBP3. Correlation analysis showed that blood IGF1 was negatively correlated with FPG, HBA1c, HOMA-IR, TyG index and positively correlated with IGFBP3. Regression analysis indicated that FPG and testosterone had a negative effect on blood IGF1 level, while HOMA-IR had no obvious effect.

Conclusion

In male patients with newly diagnosed T2D, SGLT2i can increase IGF1/IGFBP3 ratio, alleviate insulin resistance, but has no significant effect on GH and IGF1 levels. Additionally, our study showed that Metformin+SGLT2i treatment resulted in an increase in blood IGF1 levels and improved insulin resistance, suggesting a potentially beneficial role of IGF1 in newly diagnosed T2D.

R.J. Perry, G.I. Shulman, Sodium-glucose cotransporter-2 inhibitors: understanding the mechanisms for therapeutic promise and persisting risks. J. Biol. Chem. 295, 14379–14390 (2020). https://doi.org/10.1074/jbc.REV120.008387CrossRefPubMedPubMedCentral

M. Packer, S.D. Anker, J. Butler, G. Filippatos, S.J. Pocock et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413–1424 (2020). https://doi.org/10.1056/NEJMoa2022190CrossRefPubMed

H.J.L. Heerspink, B.V. Stefansson, R. Correa-Rotter, G.M. Chertow, T. Greene et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020). https://doi.org/10.1056/NEJMoa2024816CrossRefPubMed

R.C. Baxter, IGF binding proteins in cancer: mechanistic and clinical insights. Nat. Rev. Cancer. 14, 329–341 (2014). https://doi.org/10.1038/nrc3720CrossRefPubMed

S. Yakar, J.L. Liu, B. Stannard, A. Butler, D. Accili et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. USA. 96, 7324–7329 (1999). https://doi.org/10.1073/pnas.96.13.7324CrossRefPubMedPubMedCentral

S. Miyamoto, M. Nakamura, K. Yano, G. Ishii, T. Hasebe et al. Matrix metalloproteinase-7 triggers the matricrine action of insulin-like growth factor-II via proteinase activity on insulin-like growth factor binding protein 2 in the extracellular matrix. Cancer Sci. 98, 685–691 (2007). https://doi.org/10.1111/j.1349-7006.2007.00448.xCrossRefPubMed

E. Foulstone, S. Prince, O. Zaccheo, J.L. Burns, J. Harper et al. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J. Pathol. 205, 145–153 (2005). https://doi.org/10.1002/path.1712CrossRefPubMed

S.M. Firth, R.C. Baxter, Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 23, 824–854 (2002). https://doi.org/10.1210/er.2001-0033CrossRefPubMed

G. Sesti, A. Sciacqua, M. Cardellini, M.A. Marini, R. Maio et al. Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care 28, 120–125 (2005). https://doi.org/10.2337/diacare.28.1.120CrossRefPubMed

10.

M.S. Lewitt, A. Hilding, K. Brismar, S. Efendic, C.G. Ostenson et al. IGF-binding protein 1 and abdominal obesity in the development of type 2 diabetes in women. Eur. J. Endocrinol. 163, 233–242 (2010). https://doi.org/10.1530/EJE-10-0301CrossRefPubMedPubMedCentral

11.

M. Wallander, K. Brismar, J. Ohrvik, L. Ryden, A. Norhammar, Insulin-like growth factor I: a predictor of long-term glucose abnormalities in patients with acute myocardial infarction. Diabetologia 49, 2247–2255 (2006). https://doi.org/10.1007/s00125-006-0386-1CrossRefPubMed

12.

M.S. Sandhu, A.H. Heald, J.M. Gibson, J.K. Cruickshank, D.B. Dunger et al. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 359, 1740–1745 (2002). https://doi.org/10.1016/S0140-6736(02)08655-5CrossRefPubMed

13.

U. Petersson, C.J. Ostgren, L. Brudin, K. Brismar, P.M. Nilsson, Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): the Soderakra Cardiovascular Risk Factor Study. Diabetes Metab 35, 198–205 (2009). https://doi.org/10.1016/j.diabet.2008.11.003CrossRefPubMed

14.

M.S. Lewitt, A. Hilding, C.G. Ostenson, S. Efendic, K. Brismar et al. Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men. Diabetologia 51, 1135–1145 (2008). https://doi.org/10.1007/s00125-008-1016-xCrossRefPubMed

15.

C. American Diabetes Association Professional Practice, 2, Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care 45, S17–S38 (2022). https://doi.org/10.2337/dc22-S002CrossRef

16.

J.C. Levy, D.R. Matthews, M.P. Hermans, Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21, 2191–2192 (1998). https://doi.org/10.2337/diacare.21.12.2191CrossRefPubMed

17.

L. Xu, M. Wu, S. Chen, Y. Yang, Y. Wang et al. Triglyceride-glucose index associates with incident heart failure: a cohort study. Diabetes Metab. 48, 101365 (2022). https://doi.org/10.1016/j.diabet.2022.101365CrossRefPubMed

18.

S. Srinivasan, P. Singh, V. Kulothungan, T. Sharma, R. Raman, Relationship between triglyceride glucose index, retinopathy and nephropathy in Type 2 diabetes. Endocrinol. Diabetes Metab. 4, e00151 (2021). https://doi.org/10.1002/edm2.151CrossRefPubMed

19.

Z. Qin, J. Zhao, J. Geng, K. Chang, R. Liao et al. Higher triglyceride-glucose index is associated with increased likelihood of kidney stones. Front. Endocrinol. (Lausanne). 12, 774567 (2021). https://doi.org/10.3389/fendo.2021.774567CrossRefPubMedPubMedCentral

20.

American Diabetes Association Professional Practice Committee, 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care 45, S144–S174 (2022). https://doi.org/10.2337/dc22-S010CrossRef

21.

W. Lu, C. Cheng, Z. Keji, Relationship between abdominal obesity and insulin resistance, growth hormone, and insulin-like growth factor-1 in individuals with type 2 diabetes. Cell. Mol. Biol. (Noisy-le-grand). 68, 36–41 (2022). https://doi.org/10.14715/cmb/2022.68.12.8CrossRef

22.

R. Granata, Peripheral activities of growth hormone-releasing hormone. J. Endocrinol. Invest. 39, 721–727 (2016). https://doi.org/10.1007/s40618-016-0440-xCrossRefPubMed

23.

E.J. Gardner, K.A. Kentistou, S. Stankovic, S. Lockhart, E. Wheeler et al. Damaging missense variants in IGF1R implicate a role for IGF-1 resistance in the etiology of type 2 diabetes. Cell Genom. 2, None (2022). https://doi.org/10.1016/j.xgen.2022.100208CrossRefPubMed

24.

M.E. Simila, J.P. Kontto, J. Virtamo, K.A. Hatonen, L.M. Valsta et al. Insulin-like growth factor I, binding proteins -1 and -3, risk of type 2 diabetes and macronutrient intakes in men. Br. J. Nutr. 121, 938–944 (2019). https://doi.org/10.1017/S0007114519000321CrossRefPubMed

25.

S.C. Larsson, K. Michaelsson, S. Burgess, IGF-1 and cardiometabolic diseases: a Mendelian randomisation study. Diabetologia 63, 1775–1782 (2020). https://doi.org/10.1007/s00125-020-05190-9CrossRefPubMedPubMedCentral

26.

N.M. Essa, M.O. Elgendy, A. Gabr, M.M. Mahmoud, A.A. Alharbi et al. The efficacy of metformin as adjuvant to chemotherapy on IGF levels in non-diabetic female patients with progressive and non-progressive metastatic breast cancer. Eur. Rev. Med. Pharmacol. Sci 27, 5200–5210 (2023). https://doi.org/10.26355/eurrev_202306_32638CrossRefPubMed

27.

D.R. Clemmons, Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol. Metab. Clin. North Am. 41, 425–43, (2012). https://doi.org/10.1016/j.ecl.2012.04.017. vii-viiiCrossRefPubMedPubMedCentral

28.

S.N. Rajpathak, M.J. Gunter, J. Wylie-Rosett, G.Y. Ho, R.C. Kaplan et al. The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab. Res. Rev. 25, 3–12 (2009). https://doi.org/10.1002/dmrr.919CrossRefPubMedPubMedCentral

29.

G.A. Aguirre, J.L. Gonzalez-Guerra, L. Espinosa, I. Castilla-Cortazar, Insulin-like growth factor 1 in the cardiovascular system. Rev. Physiol. Biochem. Pharmacol. 175, 1–45 (2018). https://doi.org/10.1007/112_2017_8CrossRefPubMed

30.

V. Popii, G. Baumann, Laboratory measurement of growth hormone. Clin. Chim. Acta. 350, 1–16 (2004). https://doi.org/10.1016/j.cccn.2004.06.007CrossRefPubMed

31.

E. Witkowska-Sedek, B. Pyrzak, Chronic inflammation and the growth hormone/insulin-like growth factor-1 axis. Cent. Eur. J. Immunol. 45, 469–475 (2020). https://doi.org/10.5114/ceji.2020.103422CrossRefPubMed

32.

Y. Chikata, H. Iwata, K. Miyosawa, T. Koike, H. Yasuda et al. Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growth factor-1 axis. Sci. Rep. 12, 5129 (2022). https://doi.org/10.1038/s41598-022-09059-2CrossRefPubMedPubMedCentral

33.

D. Drogan, M.B. Schulze, H. Boeing, T. Pischon, Insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in relation to the risk of type 2 diabetes mellitus: results from the EPIC-Potsdam Study. Am. J. Epidemiol. 183, 553–560 (2016). https://doi.org/10.1093/aje/kwv188CrossRefPubMed

34.

N. Rachdaoui, L. Polo-Parada, F. Ismail-Beigi, Prolonged exposure to insulin inactivates Akt and Erk(1/2) and increases pancreatic islet and INS1E beta-cell apoptosis. J. Endocr. Soc. 3, 69–90 (2019). https://doi.org/10.1210/js.2018-00140CrossRefPubMed

35.

B. Brouwers, G. de Faudeur, A.B. Osipovich, L. Goyvaerts, K. Lemaire et al. Impaired islet function in commonly used transgenic mouse lines due to human growth hormone minigene expression. Cell Metab. 20, 979–990 (2014). https://doi.org/10.1016/j.cmet.2014.11.004CrossRefPubMedPubMedCentral

36.

X.C. Dong, K.D. Copps, S. Guo, Y. Li, R. Kollipara et al. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab. 8, 65–76 (2008). https://doi.org/10.1016/j.cmet.2008.06.006CrossRefPubMedPubMedCentral

37.

F. Naznin, H. Sakoda, T. Okada, H. Tsubouchi, T.M. Waise et al. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. Eur. J. Pharmacol. 794, 37–44 (2017). https://doi.org/10.1016/j.ejphar.2016.11.028CrossRefPubMed

38.

T. Kimura, A. Obata, M. Shimoda, S. Okauchi, Y. Kanda-Kimura et al. Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic beta-cells in db/db mice: The earlier and longer, the better. Diabetes Obes. Metab. 20, 2442–2457 (2018). https://doi.org/10.1111/dom.13400CrossRefPubMed

39.

Z. Huang, L. Huang, C. Wang, S. Zhu, X. Qi et al. Dapagliflozin restores insulin and growth hormone secretion in obese mice. J. Endocrinol. 245, 1–12 (2020). https://doi.org/10.1530/JOE-19-0385CrossRefPubMed

Titel: The effect of SGLT2i on the GH/IGF1 axis in newly diagnosed male T2D patients – a prospective, randomized case–control study
verfasst von: Jing Lin
Liqin Zhan
Zheng Chen
Xiaying Lin
Rongfeng Zhu
Publikationsdatum: 02.01.2024
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2024
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-023-03652-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The effect of SGLT2i on the GH/IGF1 axis in newly diagnosed male T2D patients – a prospective, randomized case–control study

Abstract

Purpose

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database

Association between rheumatoid arthritis and autoimmune thyroid disease: evidence from complementary genetic methods

Efficacy of fecal microbiota transplantation in type 2 diabetes mellitus: a systematic review and meta-analysis

The impact of body mass index on operative time in transoral endoscopic thyroidectomy vestibular approach for thyroid cancer

Re-assessment of the close relationship between serum FSH levels and semen quality: a retrospective cohort study of 11,929 Chinese men

The prevalence of positive thyroid autoantibodies in patients with subacute thyroiditis: a systematic review and meta-analysis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin